Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Avelumab in gastric cancer.

Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N.

Immunotherapy. 2019 May 6. doi: 10.2217/imt-2019-0011. [Epub ahead of print]

PMID:
31060469
2.

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.

Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T.

Cells. 2019 Apr 6;8(4). pii: E321. doi: 10.3390/cells8040321. Review.

3.

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.

Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B.

World J Clin Oncol. 2018 Dec 20;9(8):172-179. doi: 10.5306/wjco.v9.i8.172.

4.

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G.

Invest New Drugs. 2018 Dec;36(6):1133-1137. doi: 10.1007/s10637-018-0653-2. Epub 2018 Aug 7. Review.

PMID:
30083960
5.

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.

Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D.

Cells. 2018 Jul 15;7(7). pii: E76. doi: 10.3390/cells7070076. Review.

6.

Lenvatinib for the treatment of renal cell carcinoma.

Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N.

Expert Opin Investig Drugs. 2018 May;27(5):507-512. doi: 10.1080/13543784.2018.1472235. Epub 2018 May 14. Review.

PMID:
29718721
7.

Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?

Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B.

World J Clin Oncol. 2018 Apr 10;9(2):26-32. doi: 10.5306/wjco.v9.i2.26. Review.

8.

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.

Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D.

J Cell Biochem. 2018 Jun;119(6):4287-4292. doi: 10.1002/jcb.26687. Epub 2018 Mar 1.

9.

Advances in systemic therapy for malignant mesothelioma: future perspectives.

Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D.

Future Oncol. 2017 Oct;13(23):2083-2101. doi: 10.2217/fon-2017-0224. Epub 2017 Oct 6. Review.

PMID:
28984470
10.

Bevacizumab in small cell lung cancer.

Roviello G, Sobhani N, Generali D.

Ann Transl Med. 2017 Sep;5(17):361. doi: 10.21037/atm.2017.06.44. No abstract available.

11.

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.

Sobhani N, Generali D, Roviello G.

EBioMedicine. 2017 Aug;22:18-19. doi: 10.1016/j.ebiom.2017.07.003. Epub 2017 Jul 5. No abstract available.

12.

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma.

Sobhani N, Corona SP, Zanconati F, Generali D.

Genes Cancer. 2017 Mar;8(3-4):495-496. doi: 10.18632/genesandcancer.138.

Supplemental Content

Loading ...
Support Center